Despite contradictory results concerning the efficacy of this therapy form when treating severely affected COVID-19 patients [17,18,19,20,21], many countries collect and administer CP, as there are data indicating that CP is a safe and efficient therapy, providing that plasma with sufficient anti-SARS-CoV-2 antibody levels is administered early in the disease course [22,23]. Here, CP is linked to COVID-19.